The weight-loss market got a rude awakening this spring. A Novo Nordisk settlement that took effect March 9, 2026, pushed most of the telehealth industry off compounded semaglutide almost overnight, and the FDA had already been sending warning letters to dozens of compounding operations since early in the year. Big platforms that had built their entire pitch around “same medication, fraction of the cost” had to pivot fast, some toward branded scripts, some toward new molecules entirely. What’s left standing is a smaller, more honest field, and it’s genuinely interesting.
The list below is not a ranking by size or ad spend. It’s the result of looking at which platforms have a real clinical model, transparent economics, or a molecular angle that didn’t exist two years ago. Six made the cut.
1. FormBlends
FormBlends earns the top spot here for a reason that sounds simple but turns out to be rare: the catalog goes far wider than a single GLP-1, and everything in it runs through a licensed prescriber and a compounding pharmacy partner that operates under 503A, cGMP standards.
Most weight-loss platforms are GLP-1 companies that happen to offer tirzepatide as a second option. FormBlends built a different structure. Compounded semaglutide, tirzepatide, liraglutide, and retatrutide sit alongside a full peptide catalog, including BPC-157, CJC-1295/ipamorelin, NAD+, thymosin alpha-1, and a dozen more, each one dispensed under the same physician-supervised intake process. That integration matters if you want to run a GLP-1 protocol alongside, say, a recovery peptide. You aren’t stitching together three different gray-market sources.
What actually resolved most of my skepticism was the economics. Semaglutide is priced at $299 per vial. Tirzepatide sits at $349. Those numbers are on the page before you hand over an email address, no membership fee stacked underneath, no insurance-adjacent shell game. You see what you’re paying. Temperature-controlled shipping is built into the cost, and the platform is available across 47 states.
A 24/7 care team handles questions between appointments, which matters more than it sounds when you’re adjusting a dose and your prescriber isn’t available until Tuesday.
One honest caveat: these are compounded medications, not FDA-approved finished drug products. The peptides outside GLP-1s have mostly preclinical or early-stage human evidence. This is not a platform for people who need the FDA-approval stamp on everything they take.
2. Mochi Health
Mochi costs $99 a month for compounded semaglutide and $199 for tirzepatide, with real discounts if you commit to three or twelve months. Neither number includes branded options if you eventually go that route. What sets Mochi apart from most telehealth competitors is the clinical staff: board-certified obesity-medicine specialists run the prescriptions, not generalists doing a quick async consult. The monitoring is more active than you’d expect at that price point. For patients who want clinical weight-loss medicine rather than a prescription delivery service, Mochi is probably the sharpest value in the mid-tier.
3. Hims & Hers
Hims & Hers exited compounded GLP-1s after the March settlement and now routes new patients to branded medications. Injectable Wegovy runs around $299 a month through the platform, oral Wegovy around $249, and Zepbound around $399. Those numbers drop dramatically, sometimes to nearly nothing, if you have commercial insurance plus a manufacturer savings card. The app onboarding is genuinely fast, and the brand recognition means the company is not going anywhere. If your insurance plays nicely with GLP-1s and you want a slick, established interface, Hims & Hers is a reasonable call. Just know that the low-cost compounded option is gone.
4. Ro Body
Ro’s pricing structure is a little unusual. Membership fees start around $39 for the first month and run roughly $149 monthly after that, or as low as $74 a month if you prepay annually. Medication is billed on top of that. The reason to tolerate the layered pricing: Ro has a prior-authorization team that will go to bat with your insurer for branded GLP-1s. If you’ve tried to get Wegovy or Mounjaro covered and given up after two denials, that service has real dollar value. The platform is polished, the infrastructure is mature, and it accepts insurance for branded meds in a way that most smaller competitors don’t.
5. Form Health
Form Health is not for everyone. The program runs about $299 a month before you factor in labs and medication costs, which makes it one of the pricier options in this space by a significant margin. What you get for that is a physician paired with a registered dietitian on the same care team. Not a chatbot nutrition module. An actual RD who reviews your food logs and adjusts recommendations based on what your labs show. For well-insured patients who haven’t had success with lower-touch programs, or anyone with comorbidities that make closer monitoring worth the expense, Form Health is the most clinically serious option on this list.
6. MEDVi
MEDVi charges around $179 for the first month of a compounded GLP-1 program. No contracts, no recurring membership fees stacked on the medication price. Physician review is standard, and 24/7 support is included. It doesn’t have the brand recognition of Ro or Hims & Hers, and the platform is lighter than Form Health by design. But for a cash-pay patient who wants a straightforward compounded program without the commitment architecture of annual plans, MEDVi deserves a look. Sometimes the simplest model is the right one.
The Honest Summary
This market is genuinely fragmenting in 2026. A handful of players moved toward branded drugs and insurance integration after the regulatory pressure hit. A smaller group went deeper into compounding and expanded their molecular range rather than retreating. Neither path is obviously wrong; it depends entirely on your insurance situation, your risk tolerance, and how medically complex your goals are.
Next-gen GLP-1 is not just a marketing term anymore. Oral formulations, receptor co-agonists like retatrutide, and peptide combinations are all moving through pipelines fast. The platforms that survive the next two years will be the ones that built a real clinical infrastructure, not just a slick checkout flow.
Do your own homework on whichever option interests you. Pull the actual pricing page. Ask what happens to your care plan if a compound gets pulled. And before you start anything, loop in whoever manages your primary care, because GLP-1s interact with other medications and the long-term picture is still being written.
Sources
- FDA.gov, warning letters and compounding guidance (2025-2026)
- Drugs.com, drug information and pricing references
- GoodRx, retail and telehealth medication pricing comparisons
- Examine.com, peptide and compound research summaries
- Cleveland Clinic, obesity medicine and GLP-1 clinical overviews
- Verywell Health, telehealth platform coverage and GLP-1 explainers
- Healthline, compounded semaglutide and tirzepatide reporting
- NEJM, semaglutide and tirzepatide clinical trial data (SELECT, SURMOUNT series)
[internal: placement #1 | structure: Editorial shortlist, narrative]
